Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MYKROX | Chartwell Pharmaceuticals | N-019532 DISCN | 1987-10-30 | 1 products |
DIULO | G.D. Searle | N-018535 DISCN | 1982-01-01 | 3 products |
ZAROXOLYN | i3 Pharmaceuticals | N-017386 DISCN | 1982-01-01 | 3 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
metolazone | ANDA | 2024-08-01 |
mykrox tablets | 2006-01-12 | |
zaroxolyn | New Drug Application | 2016-08-06 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | HP_0001635 | I50 | 1 | 2 | 4 | 13 | 5 | 25 |
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 2 | 3 |
Acute liver failure | D017114 | HP_0004448 | — | — | — | — | 2 | 1 | 3 |
Covid-19 | D000086382 | — | U07.1 | — | — | — | 1 | 1 | 2 |
Iron overload | D019190 | — | — | — | 1 | — | 1 | — | 2 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | 1 | — | 1 |
Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | 1 | — | 1 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
Edema | D004487 | HP_0000969 | R60.9 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
Critical illness | D016638 | — | — | — | 1 | — | — | — | 1 |
Sepsis | D018805 | HP_0100806 | A41.9 | — | 1 | — | — | — | 1 |
Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
Hypernatremia | D006955 | HP_0003228 | E87.0 | — | — | — | — | 1 | 1 |
Drug common name | Metolazone |
INN | metolazone |
Description | Metolazone is a quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics. It has a role as a diuretic, an antihypertensive agent and an ion transport inhibitor. It is a member of quinazolines, an organochlorine compound and a sulfonamide. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C |
PDB | — |
CAS-ID | 17560-51-9 |
RxCUI | — |
ChEMBL ID | CHEMBL878 |
ChEBI ID | 64354 |
PubChem CID | 4170 |
DrugBank | DB00524 |
UNII ID | TZ7V40X7VX (ChemIDplus, GSRS) |